BOCA RATON, Fla., Oct. 31, 2018 /PRNewswire/ -- iMorph Smart Technologies, Inc. (iMorph) www.imorphed.com, is a privately held company that integrates wearable smart technology to automate self-help psychology to stop or reduce undesirable negative personal behaviors. iMorph announced today its flagship smoking cessation product, CigFree SmartBand, is being readied as a prototype for its clinical trial to demonstrate efficacy for quitting smoking.
Adrian Vargas, CEO, reported, "The smoking cessation market in the US is reaching $7 billion annually. There are 38 million cigarette smokers in America. 40% will attempt to stop each year. 7% succeed of which, half relapse. Current solutions include: expensive drugs that block neuroreceptors to wean smokers off cigarettes; Ingesting nicotine as a replacement therapy that is costly and generally ongoing; and Vaping e-cigarettes to replace cigarette smoking. Reports show vaping is causing other health problems, and are a costly undertaking. Smoking is one of the biggest killers. Approximately $170 billion and $150 million is spent annually on related health problems and lost productivity respectively."
Younis Zubchevich, COO, added, "We have configured CigFree, our first-generation smart wearable device prototype to detect the act of smoking in real time. We've paired our smartBand with our Phone App, and enable smokers to record, in their own voice, a series of affirmations regarding personal health choices. When CigFree detects the act of smoking, it signals the App to notify smokers to listen to their prerecorded messages while smoking, ensuring CigFree's self-help solution is delivered exactly the time it is needed. Other solutions and Apps require full attention to implement. CigFree is seamless, automated for ease of use and never forgets to remind smokers. Affirmations have been successfully used by people for centuries to achieve specific personal goals."
Younis Zubchevich continued, "iMorph, with two Credentialed investigators, will conduct an IRB approved 30-day open-label design study to assess the extent to which use of CigFree leads to a significantly greater cessation or reduction of smoking. Efficacy will be based on daily reports of cigarette usage and researchers' findings of baseline-ending changes in blood pressure, oxygen saturation and pulmonary functioning typically found among people who have stopped smoking."
Contact: Younis Zubchevich
561 414 6371
SOURCE iMorph Smart Technologies, Inc.